BioCryst Pharmaceuticals Stock Income Statements

BioCryst Pharmaceuticals Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

Net Income

BioCryst Pharmaceuticals Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-09-30	2005-06-30	2005-03-31	2004-09-30	2004-06-30	2002-12-31

revenues	163,353,000	145,534,000	131,534,000	117,085,000	109,332,000	92,761,000	93,401,000	86,742,000	82,491,000	68,778,000
expenses:
cost of product sales	2,798,000	4,568,000	6,094,000	3,211,000	1,699,000	1,265,000	1,557,000	1,099,000	894,000	931,000	1,006,250	3,543,000	246,000	236,000	1,702,750	591,000	297,000	5,923,000	379,250	1,517,000						1,399,000
research and development	43,386,000	37,270,000	49,441,000	41,081,000	37,623,000	46,493,000	70,052,000	46,879,000	51,247,000	48,388,000	73,207,000	52,740,000	61,990,000	65,360,000	63,529,000	49,971,000	52,873,000	42,435,000	35,354,000	30,245,000	27,498,000	29,867,000	81,948,000	25,120,000	27,681,000	27,493,000	62,882,000	22,006,000	21,010,000	18,441,000	49,453,000	17,509,000	15,759,000	16,770,000	46,903,000	14,105,000	14,166,000	20,579,000	52,691,000	20,067,000	16,524,000	17,120,000	38,760,000	13,036,000	11,067,000	9,183,000	34,753,000	7,977,000	11,728,000	7,411,000	39,392,000	12,072,000	12,777,000	15,441,000	42,126,000	14,772,000	13,975,000	12,932,000	63,276,014	19,197,000	14,737,000	24,917,000	54,120,442	18,181,000	11,213,000	11,289,000	57,330,634	15,996,000	13,373,000	21,898,000	64,321,996	29,730,000	19,013,000	16,195,000	30,433,372	16,650,000	11,190,000	8,043,000	7,164,000	5,263,000	5,175,000	4,838,000	4,348,000
selling, general and administrative	87,383,000	82,469,000	80,470,000	65,084,000	61,214,000	59,364,000	64,382,000	50,648,000	50,997,000	47,867,000	50,153,000	36,919,000	38,017,000	34,282,000	35,387,000	34,992,000	26,325,000	22,114,000	20,986,000	17,195,000	13,883,000	15,865,000	25,386,000	11,735,000															10,316,000	2,731,000
total operating expenses	133,567,000	124,307,000	136,042,000	109,393,000	100,571,000	107,249,000	136,071,000	98,663,000	103,194,000	97,193,000	125,856,000	93,272,000	100,254,000	99,880,000	99,335,000	85,578,000	79,541,000	70,436,000	56,421,000	48,966,000	41,381,000	45,801,000	111,417,000	36,873,000	36,366,000	35,217,000	84,926,000	29,947,000	30,745,000	26,190,000	60,488,000	22,109,000	18,615,000	20,122,000	57,956,000	17,004,000	16,917,000	23,868,000	63,552,000	24,149,000	20,500,000	21,256,000	44,531,000	14,848,000	13,085,000	10,844,000	38,734,000	9,314,000	12,963,000	8,870,000
income from operations	29,786,000	21,227,000	-4,508,000	7,692,000	8,761,000	-14,488,000	-42,670,000	-11,921,000	-20,703,000	-28,415,000	-46,311,000	-17,445,000	-34,722,000	-49,957,000	-52,177,000	-44,584,000	-29,582,000	-51,377,000	-52,405,000	-42,864,000	-38,510,000	-40,978,000	-64,357,000	-35,098,000	-34,918,000	-29,330,000	-65,727,000	-28,493,000	-18,251,000	-22,214,000	-44,062,000	-13,349,000	-15,516,000	-10,685,000	-39,366,000	-9,241,000	-12,130,000	-19,048,000	-26,282,000	-13,162,000	5,342,000	-14,430,000	-34,161,000	-11,610,000	-11,619,000	-7,386,000	-23,792,000	-6,925,000	-12,142,000	-5,316,000	-25,872,000	-8,016,000	-10,176,000	-5,001,000	-36,782,000	-12,805,000	-14,243,000	-11,499,000	-23,366,718	-10,990,000	-10,330,000	-2,729,000	-3,040,224	-10,697,000	-8,739,000	-9,387,000	-17,591,492	-9,573,000	-13,380,000	-14,016,000	-20,418,057	-11,862,000	-7,582,000	-9,408,000	-30,520,809	-16,459,000	-11,016,000	-8,767,000	-7,927,000	-5,932,000	-5,830,000
yoy	239.98%	-246.51%	-89.44%	-164.52%	-142.32%	-49.01%	-7.86%	-31.67%	-40.37%	-43.12%	-11.24%	-60.87%	17.38%	-2.76%	-0.44%	4.01%	-23.18%	25.38%	-18.57%	22.13%	10.29%	39.71%	-2.08%	23.18%	91.32%	32.03%	49.17%	113.45%	17.63%	107.90%	11.93%	44.45%	27.91%	-43.90%	49.78%	-29.79%	-327.07%	32.00%	-23.06%	13.37%	-145.98%	95.37%	43.58%	67.65%	-4.31%	38.94%	-8.04%	-13.61%	19.32%	6.30%	-29.66%	-37.40%	-28.55%	-56.51%	57.41%	16.52%	37.88%	321.36%	668.59%	2.74%	18.21%	-70.93%	-82.72%	11.74%	-34.69%	-33.03%	-13.84%	-19.30%	76.47%	48.98%	-33.10%	-27.93%	-31.17%	7.31%	285.02%	177.46%	88.95%
qoq	40.32%	-570.87%	-158.61%	-12.20%	-160.47%	-66.05%	257.94%	-42.42%	-27.14%	-38.64%	165.47%	-49.76%	-30.50%	-4.25%	17.03%	50.71%	-42.42%	-1.96%	22.26%	11.31%	-6.02%	-36.33%	83.36%	0.52%	19.05%	-55.38%	130.68%	56.12%	-17.84%	-49.58%	230.08%	-13.97%	45.21%	-72.86%	325.99%	-23.82%	-36.32%	-27.52%	99.68%	-346.39%	-137.02%	-57.76%	194.24%	-0.08%	57.31%	-68.96%	243.57%	-42.97%	128.40%	-79.45%	222.75%	-21.23%	103.48%	-86.40%	187.25%	-10.10%	23.86%	-50.79%	112.62%	6.39%	278.53%	-10.24%	-71.58%	22.41%	-6.90%	-46.64%	83.76%	-28.45%	-4.54%	-31.35%	72.13%	56.45%	-19.41%	-69.18%	85.44%	49.41%	25.65%	10.60%	33.63%	1.75%
operating margin %
other income:
interest income	2,516,000	3,024,000	3,570,000	3,591,000	3,554,000	4,031,000
interest expense	-21,582,000	-23,494,000	-24,449,000	-24,828,000	-24,733,000	-24,506,000	-24,583,000	-27,345,000	-28,915,000	-27,396,000	-26,458,000	-24,775,000	-24,022,000	-23,837,000	-18,780,000	-14,115,000	-13,495,000	-12,904,000	-5,609,000	-2,927,000	-2,918,000	-3,047,000	-8,848,000	-3,044,000	-3,035,000	-2,726,000	-6,830,000	-2,346,000	-2,195,000	-2,221,000	-6,425,000	-2,140,000	-2,094,000	-2,100,000	-5,022,000	-1,465,000	-1,421,000	-1,470,000	-3,959,000	-1,241,000	-1,306,000	-1,315,000	-3,781,000	-1,217,000	-1,225,000	-1,242,000	-3,587,000	-1,191,000	-1,165,000	-1,180,000	-3,500,000	-1,166,000	-1,160,000	-1,160,000	-2,614,000	-1,160,000	-1,166,000	-288,000
foreign currency losses	-63,000					-51,000	-374,000	-737,000		-229,000	-1,400,000	-538,000		-177,000
loss on extinguishment of debt	-4,171,000						-7,254,750		-29,019,000
total other income	-23,300,000	-20,469,000
income before income taxes	6,486,000	758,000	-25,991,000	-13,447,000	-12,502,000	-35,014,000	-63,162,000	-35,819,000	-74,586,000	-52,662,000	-71,465,000	-40,998,000	-58,003,000	-73,917,000
income tax expense	1,401,000	726,000	804,000	586,000	172,000	365,000	-1,431,000	330,000	740,000	671,000	76,000	1,522,000	856,000	279,000
net income	5,085,000	32,000	-26,795,000	-14,033,000	-12,674,000	-35,379,000	-61,731,000	-36,149,000	-75,326,000	-53,333,000	-71,541,000	-42,520,000	-58,859,000	-74,196,000	-17,779,000	-58,801,000	-43,198,000	-64,284,000	-60,493,000	-46,115,000	-38,607,000	-37,599,000	-71,305,000	-37,592,000	-37,629,000	-31,054,000	-71,655,000	-29,597,000	-18,446,000	-25,777,000	-50,648,000	-15,134,000	-16,886,000	-14,219,000	-43,616,000	-11,528,000	-16,281,000	-22,832,000	-28,398,000	-14,621,000	4,901,000	-15,164,000	-36,458,000	-8,731,000	-14,649,000	-10,137,000	-22,107,000	-8,001,000	-12,172,000	-4,506,000	-29,381,000	-9,700,000	-12,276,000	-6,052,000	-42,489,000	-14,459,000	-16,271,000	-13,027,000	-22,989,183	-10,864,000	-10,193,000	-2,595,000	-2,824,535	-10,627,000	-8,684,000	-9,292,000	-15,736,570	-8,995,000	-12,709,000	-13,098,000	-18,071,524	-10,984,000	-6,963,000	-8,825,000	-28,014,853	-15,603,000	-10,083,000	-7,882,000	-7,645,000	-5,648,000	-5,645,000	-5,296,000	-5,057,000
yoy	-140.12%	-100.09%	-56.59%	-61.18%	-83.17%	-33.66%	-13.71%	-14.98%	27.98%	-28.12%	302.39%	-27.69%	36.25%	15.42%	-70.61%	27.51%	11.89%	70.97%	-15.16%	22.67%	2.60%	21.08%	-0.49%	27.01%	104.00%	20.47%	41.48%	95.57%	9.24%	81.29%	16.12%	31.28%	3.72%	-37.72%	53.59%	-21.15%	-432.20%	50.57%	-22.11%	67.46%	-133.46%	49.59%	64.92%	9.12%	20.35%	124.97%	-24.76%	-17.52%	-0.85%	-25.55%	-30.85%	-32.91%	-24.55%	-53.54%	84.82%	33.09%	59.63%	402.00%	713.91%	2.23%	17.38%	-72.07%	-82.05%	18.14%	-31.67%	-29.06%	-12.92%	-18.11%	82.52%	48.42%	-35.49%	-29.60%	-30.94%	11.96%	266.45%	176.26%	78.62%	48.83%	51.18%
qoq	15790.63%	-100.12%	90.94%	10.72%	-64.18%	-42.69%	70.77%	-52.01%	41.24%	-25.45%	68.25%	-27.76%	-20.67%	317.32%	-69.76%	36.12%	-32.80%	6.27%	31.18%	19.45%	2.68%	-47.27%	89.68%	-0.10%	21.17%	-56.66%	142.10%	60.45%	-28.44%	-49.11%	234.66%	-10.38%	18.76%	-67.40%	278.35%	-29.19%	-28.69%	-19.60%	94.23%	-398.33%	-132.32%	-58.41%	317.57%	-40.40%	44.51%	-54.15%	176.30%	-34.27%	170.13%	-84.66%	202.90%	-20.98%	102.84%	-85.76%	193.86%	-11.14%	24.90%	-43.33%	111.61%	6.58%	292.79%	-8.13%	-73.42%	22.37%	-6.54%	-40.95%	74.95%	-29.22%	-2.97%	-27.52%	64.53%	57.75%	-21.10%	-68.50%	79.55%	54.75%	27.92%	3.10%	35.36%	0.05%	6.59%	4.73%
net income margin %
other comprehensive income:
foreign currency translation adjustment	702,000	366,000	-946,000	563,000	-140,000	-253,000	247,000	-185,000	59,000	59,000	13,000	695,000	104,000	78,000	75,000	28,000	-92,000	178,000
unrealized loss on available for sale investments	-188,000	-155,000									111,000	-808,000	-275,000																		-500	-2,000	-12,000													-2,000
total other comprehensive income	514,000	211,000
net comprehensive income	5,599,000	243,000
net income per common share: basic	20	0
weighted-average shares of common stock outstanding: basic	209,519,000	208,882,000
net income per common share: diluted	20	0
weighted-average shares of common stock outstanding: diluted	219,886,000	215,261,000
foreign currency gains		1,000	-9,250	98,000	-84,000				301,000				132,000
royalty			37,000	17,000	35,000	127,000	80,000	37,000	56,000	7,000	113,000	70,000	1,000	2,000	1,000	24,000	46,000	-36,000	48,000	9,000		69,000	357,000	18,000	26,000	87,000	453,000	18,000	243,000	140,000	445,000	115,000	22,000	294,000	259,000	143,000	27,000	77,000	523,000	5,000	442,000	60,000	116,000	5,000	5,000	73,000			4,000	77,000
unrealized gain on available for sale investments			-426,000	1,173,000	-74,000	-313,000	290,000	295,000	46,000	500,000				-69,000	-12,000	-1,000	-3,000	1,000	-6,000	6,000		-25,000	317,000	19,000	130,000	208,000	-96,000	42,000	24,000	-233,000				9,000	218,000	-24,000	-2,000	254,000	22,750	91,000	-102,000	140,000								-12,000
net comprehensive loss			-28,167,000	-12,297,000	-12,888,000	-35,945,000																-37,624,000				-30,846,000
basic and diluted net income per common share			-130	-70	-60	-170	-310	-190	-400	-280	-380	-230	-320	-400	-100	-330	-240	-360	-340	-260	-240	-240	-600	-340	-340	-280	-700	-280	-190	-260	-600	-180	-210	-190	-590	-160		-310	-390	-200		-210	-560	-120	-230	-170	-410	-140	-230	-90					-940	-320	-360	-290	239.24	-240	-230	-60	279.65	-280	-230	-240	239.35	-240	-330	-340	319.11	-320	-240	-300	528.5	-530	-350	-270
weighted-average shares outstanding			206,696,000	206,905,000	206,425,000	206,064,000	192,198,000	189,644,000	189,118,000	188,509,000	185,908,000	186,180,000	185,605,000	184,898,000	179,117,000	179,106,000	178,127,000	177,343,000	167,267,000	176,521,000	161,569,000	154,156,000	115,600,000	110,416,000	110,338,000	110,167,000	103,185,000	105,410,000	98,787,000	98,592,000	84,451,000	83,570,000	80,418,000	75,167,000	73,699,000	73,734,000		73,601,000	72,901,000	73,262,000		72,341,000	66,773,000	71,801,000	63,647,000	59,589,000	55,216,000	57,124,000	53,468,000	51,073,000	49,474,000					45,178,000	45,111,000	44,987,000	44,564,177	44,884,000	44,517,000	43,925,000	38,925,525	38,460,000	38,232,000	38,204,000	38,062,131	38,095,000	38,117,000	38,059,000	32,770,923	34,277,000	29,420,000	29,274,000	29,147,397	29,222,000	29,184,000	28,938,000	26,209,000	26,149,000	23,620,000	21,706,000	21,618,000
interest and other income							4,465,000	4,184,000	3,750,000	3,378,000	2,704,000	1,760,000	609,000	54,000	14,000	9,000	13,000	26,000			2,758,000	6,446,000	1,531,000	402,000	547,000	596,000	1,641,000	611,000	493,000	462,000	790,000	225,000	203,000	109,000	684,000	109,000	147,000	439,000	401,000	134,000	116,000	117,000	79,000	14,000	19,000	17,000	75,000	18,000	21,000	33,000	168,000	54,000	57,000	71,000	321,000	92,000	136,000	102,000	377,535	126,000	137,000	134,000	215,689	70,000	55,000	95,000	1,854,922	578,000	671,000	918,000	2,346,533	878,000	619,000	583,000	2,505,956	856,000	933,000	885,000	282,000	284,000	185,000
comprehensive loss							-41,008,500	-36,039,000	-75,221,000	-52,774,000	-43,962,500	-42,633,000	-59,030,000	-74,187,000	-41,543,000	-58,774,000	-43,293,000	-64,105,000	-30,587,750	-46,109,000	-38,618,000		-9,393,250	-37,573,000	-37,499,000		-7,388,750	-29,555,000	-18,422,000	-26,010,000	-50,877,000	-15,136,000	-16,898,000	-14,210,000	-43,398,000	-11,552,000		-22,578,000	-28,565,000	-14,530,000		-15,024,000	-36,591,000	-8,732,000	-14,648,000	-10,139,000	-22,126,000	-8,005,000	-12,181,000	-4,518,000	-29,394,000	-9,700,000	-12,285,000	-6,043,000
product sales											78,063,000	75,213,000	64,888,000	49,546,000	45,908,000	39,141,000	33,430,000	17,871,000	605,000	2,478,000		218,000	17,198,000	335,000		1,679,000						1,501,000							592,000	5,699,000		537,000																				325,000
royalty revenue											1,416,000	600,000	540,000	347,000	347,000	322,000	128,000	-897,000	1,138,000	254,000	44,000	1,945,000	5,795,000	508,000	696,000	2,322,000	5,578,000	523,000	142,000	3,661,000	10,101,000	442,000	489,000	6,321,000	6,181,000	3,501,000	629,000	1,890,000	2,260,000	126,000	132,000	1,518,000			125,000	1,821,000	2,554,000	8,000	110,000	1,924,000	469,000	2,848,000
milestone revenue																	15,000,000
collaborative and other research and development											66,000	14,000	104,000	30,000	903,000	1,531,000	1,401,000	2,085,000	2,273,000	3,370,000	2,827,000	2,660,000	24,067,000	932,000	752,000	1,886,000	13,621,000	931,000	12,352,000	315,000	6,325,000	6,817,000	2,610,000	3,116,000	10,140,000	4,262,000	4,158,000	2,930,000	34,418,000	5,162,000	25,710,000	4,771,000	7,317,000	3,233,000	1,341,000	1,637,000	12,388,000	2,381,000	711,000	1,630,000	20,063,000	2,913,000	4,210,000	12,221,000	14,394,000	5,249,000	3,735,000	5,435,000	50,056,336	12,000,000	7,616,000	25,035,000	41,118,811	10,548,000	4,787,000	4,359,000	47,667,369	8,894,000	2,659,000	10,768,000	50,774,901	20,463,000	13,444,000	9,159,000	4,421,936	1,790,000	1,558,000	771,000	32,000	58,000	41,000	116,000	43,000
total revenues											79,545,000	75,827,000	65,532,000	49,923,000	47,158,000	40,994,000	49,959,000	19,059,000	4,016,000	6,102,000	2,871,000	4,823,000	47,060,000	1,775,000	1,448,000	5,887,000	19,199,000	1,454,000	12,494,000	3,976,000	16,426,000	8,760,000	3,099,000	9,437,000	18,590,000	7,763,000	4,787,000	4,820,000	37,270,000	10,987,000	25,842,000	6,826,000	10,370,000	3,238,000	1,466,000	3,458,000	14,942,000	2,389,000	821,000	3,554,000	20,532,000	5,761,000	4,210,000	12,221,000	14,394,000	5,249,000	3,735,000	5,435,000	50,381,336	12,000,000	7,616,000	26,071,000																				270,000	217,000
expenses
gain on foreign currency															-68,500	-111,000	-134,000
loss on foreign currency																		-29,000
interest and other income and expense																			2,223,000	-312,000
gain on foreign currency derivative																			7,750	-12,000	63,000	-20,000	369,000	148,000	-223,000	406,000	157,750	631,000	1,507,000		-951,000	130,000	521,000		88,000	-931,000	-2,877,000	-2,753,000	1,442,000	-352,000	749,000	464,000	1,405,000	4,082,000	-1,824,000	-1,526,000	5,197,000	97,000	1,114,000	1,957,000				38,000
unrealized (loss) gain on available for sale investments																					-11,000
general and administrative																									8,659,000	6,238,000	1,980,750	7,923,000	9,492,000	7,609,000	835,750	3,343,000	2,834,000	3,058,000	689,000	2,756,000	2,724,000	3,212,000			3,534,000	4,061,000	5,649,000	1,812,000	2,013,000	1,588,000	3,883,000	1,337,000	1,231,000	1,382,000	5,235,000	1,591,000	1,609,000	1,781,000	9,050,000	3,282,000	4,003,000	4,002,000	10,385,581	3,793,000	3,209,000	3,797,000	8,417,187	3,064,000	2,313,000	2,457,000	7,928,227	2,471,000	2,666,000	2,886,000	6,870,962	2,595,000	2,013,000	2,372,000	4,509,373	1,599,000	1,384,000	1,495,000	795,000	727,000	696,000	728,000	926,000
cost of products sold																																1,142,000							22,000	1,346,000		15,000																				86,000
loss on foreign currency derivative																														-1,804,000				-1,543,000																	-177,000	-572,000	-997,000		-3,414,000	-586,000	-998,000	-1,342,000
basic net income per common share																																					-220				70
diluted net income per common share																																					-220				60
weighted-average shares outstanding, basic																																					73,695,000				72,642,000
weighted-average shares outstanding, diluted																																					73,695,000				76,760,000
comprehensive income																																					-16,283,000				4,799,000
unrealized loss on investments																																											-250	-1,000			-1,000	-4,000	-9,000
unrealized gain on investments																																													1,000								-9,000	9,000
royalty expense																																																			28,500	114,000
total expenses																																																			3,444,250	13,777,000	14,386,000	17,222,000	4,513,500	18,054,000	17,978,000	16,934,000	73,748,054	22,990,000	17,946,000	28,800,000	67,081,543	21,245,000	13,526,000	13,746,000	65,258,861	18,467,000	16,039,000	24,784,000	71,192,958	32,325,000	21,026,000	18,567,000	34,942,745	18,249,000	12,574,000	9,538,000	7,959,000	5,990,000	5,871,000	5,566,000	5,274,000
royalties																																																														711,000
revenues:
amounts per common share:
basic and diluted net income																																																																															-290	-220	-240
interest and other																																																																																		154,000	174,000

We provide you with 20 years income statements for BioCryst Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BioCryst Pharmaceuticals stock. Explore the full financial landscape of BioCryst Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about BioCryst Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.